Abstract
Infection with hepatitis B virus (HBV) can now be prevented through the use of several effective vaccines (Maynard et al. 1989). Yet for the millions of existing chronic carriers there is no effective treatment to clear the virus and thus limit the high risk of liver diseases associated with long-term infection; chronic hepatitis, cirrhosis, and hepatocellular carcinoma. A number of recent reviews have described the limited success of current antiviral therapies of patients chronically infected with hbv (Alexander and Williams 1988; Lever 1988; Garcia and Gentry 1989; Di Bisceglie and Hoofnagle 1989). The focus of this chapter will be on understanding why HBV is difficult to eradicate once chronic infection is established, on possible new targets for antiviral therapy in the life cycle of HBV, and on recently developed models for testing the efficacy of anti-hepadnaviral treatments.KeywordsHepatitis Delta VirusWoodchuck Hepatitis VirusDuck HepatitisAdenine ArabinosidePrimary Duck HepatocyteThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
